source
- Roivant's FcRn drug IMVT-1402 fails Phase 2b lupus trialRoivant announced that its FcRn-targeting antibody IMVT-1402 (imeroprubart) failed to meet primary endpoints in a Phase 2b trial in patients with lupus. The study did not show improvement in disea…
- Job postings in Pennsylvania’s biopharma sector surge 213% as nine companies ramp up hiringJob postings for biopharma roles in Pennsylvania have jumped dramatically, with BioSpace reporting a 213% year‑over‑year increase in August and overall postings tripling compared with the previous…